CZ298027B6 - Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu - Google Patents
Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu Download PDFInfo
- Publication number
- CZ298027B6 CZ298027B6 CZ0286599A CZ286599A CZ298027B6 CZ 298027 B6 CZ298027 B6 CZ 298027B6 CZ 0286599 A CZ0286599 A CZ 0286599A CZ 286599 A CZ286599 A CZ 286599A CZ 298027 B6 CZ298027 B6 CZ 298027B6
- Authority
- CZ
- Czechia
- Prior art keywords
- epothilone
- oxides
- oxide
- epothilones
- per
- Prior art date
Links
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title claims abstract description 6
- 229930013356 epothilone Natural products 0.000 title claims description 16
- 150000001204 N-oxides Chemical class 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- -1 Epothilone N-oxide Chemical class 0.000 claims description 7
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 7
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000004965 peroxy acids Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Silicon Polymers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
Zpusob prípravy epothilon-N-oxidu, pri nemž se chránený nebo nechránený epothilon A nebo B prevede na N-oxid, zejména peroxykyselinou nebo dioxiranem. Epothilon A-N-oxid a epothilon B-N-oxid.
Description
Způsob přípravy epothilon-N-oxidů a N-oxidy epothilonů
Oblast techniky
Epothiolony A a B jsou známé; srovnej například DE 4 138 042, WO 93 10121 a WO 97 19086. Jmenovaný stav techniky je navrhuje jako terapeutické prostředky.
Dosavadní stav techniky
V PNAS USA 95 (1998) 1369 - 1374 jsou epothilony označovány jako užitečné terapeutické prostředky. V důsledku jejich terapeutických efektů se podle Angew. Chem. Int. Ed. 36 (1997) 2097 - 2103 bude dokonce opatřovat obsáhlá knihovna sloučenin tohoto druhu (extensive library of compounds).
Podstata vynálezu
Vynález se týká způsobu přípravy epothilon-N-oxidů, při němž se chráněný nebo nechráněný epothilon A nebo B o sobě známým způsobem převede na N-oxid.
Tento postup podle vynálezu je s výhodou charakterizován tím že se N-oxidace provádí peroxykyselinou nebo dioxiranem.
Předmětem vynálezu je rovněž epothilon-N-oxid (epothilon A-N-oxid) vzorce
r1, r2 = h, z = o; r = h
Dále je předmětem vynálezu epothilon-N-oxid (epothilon B-N-oxid) vzorce:
r1,r2 = h, z = o; r = ch3
-1 CZ 298027 B6
Příklady provedení vynálezu
Příklad 1
Epothilon A-N-oxid
Ke 100 mg epothilonu A v 1 ml dichlormetanu bylo přidáno 100 mg 70% kyseliny w-chlorperoxybenzoové v 0,5 ml dichlorethanu. Po 6 hodinách míchání při teplotě místnosti bylo zředěno dichlormethanem a postupně vytřepáváno roztokem siřičitanu sodného a roztokem bikarbonátu sodného k odstranění přebytečné peroxykyseliny. Rozpouštědlo bylo odpařeno ve vakuu a zbytek byl rozdělen preparativní HPLC na sloupci Nucleosilu RP-18 (250 x 20 mm, mobilní fáze methanol/voda 60:40). Výtěžek 60 mg bezbarvého oleje.
Rf= 0,60 (silikagel DC Alufolie, mobilní fáze dichlormethan/methanol 1:1);
ESI-MS (negativní ionty) m/z 510;
UV (methanol): Zmax = 240 nm;
13C-NMR (CDC13): C-l 70,5, C-2 39,9, C-3 70,8, C^l 55,1, C-5 221,4, C-6 40,9, C-7 72,9, C8 37,6, C-9 31,8, C-10 22,8, C-l 1 28,0, C-12 58,0, C-13 55,8, C-14 32,2, C-15 75,5, C-16 144,5, C-17 111,4, C-18 143, 4, C-19 110,3, C-20 145,6, C-21 13,5, C-22 15,4, C-23 23,3, C24 12,0, C-25 16,5, C-27 18,2 ppm.
Příklady syntéz
Epothilon A-N-oxid: R1, R2 = H, Z = O', R = H
Epothilon B-N-oxid: R1, R2 = H, Z = O', R = CH3
Claims (4)
1. Způsob přípravy epothilon-N-oxidů, vyznačený tím, že se 3,7-chráněný nebo nechráněný epothilon A nebo B o sobě známým způsobem převede na N-oxid.
2. Způsob podle nároku 1,vyznačený tím, že se N-oxidace provádí peroxykyselinou nebo dioxiranem.
3. Epothilon-N-oxid (epothilon A-N-oxid) vzorce:
kde R1, R2 = H, Z = O ; R = H
4. Epothilon-N-oxid (epothilon B-N-oxid) vzorce:
kde R1, R2 = H, Z = O“, R = CH3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19707505 | 1997-02-25 | ||
| PCT/EP1998/001060 WO1998038192A1 (de) | 1997-02-25 | 1998-02-25 | Seitenkettenmodifizierte epothilone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ286599A3 CZ286599A3 (cs) | 2000-03-15 |
| CZ298027B6 true CZ298027B6 (cs) | 2007-05-30 |
Family
ID=7821415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ0286599A CZ298027B6 (cs) | 1997-02-25 | 1998-02-25 | Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6359140B1 (cs) |
| EP (2) | EP0975638B1 (cs) |
| JP (1) | JP2001513098A (cs) |
| KR (1) | KR100494179B1 (cs) |
| CN (2) | CN1128803C (cs) |
| AR (1) | AR011878A1 (cs) |
| AT (1) | ATE221888T1 (cs) |
| AU (1) | AU736062B2 (cs) |
| BR (1) | BR9807742B1 (cs) |
| CA (1) | CA2281105A1 (cs) |
| CZ (1) | CZ298027B6 (cs) |
| DE (2) | DE19880193D2 (cs) |
| DK (1) | DK0975638T3 (cs) |
| ES (1) | ES2183338T3 (cs) |
| HU (1) | HU228851B1 (cs) |
| IL (1) | IL131343A (cs) |
| NO (1) | NO327211B1 (cs) |
| NZ (1) | NZ337195A (cs) |
| PL (1) | PL190422B1 (cs) |
| PT (1) | PT975638E (cs) |
| RU (1) | RU2201932C2 (cs) |
| TW (1) | TW480263B (cs) |
| WO (1) | WO1998038192A1 (cs) |
| ZA (1) | ZA981575B (cs) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59610712D1 (de) | 1995-11-17 | 2003-10-16 | Biotechnolog Forschung Gmbh | Epothilonderivate, herstellung und verwendung |
| KR100538095B1 (ko) | 1996-11-18 | 2005-12-21 | 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) | 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도 |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| JP4579351B2 (ja) | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| PT975638E (pt) * | 1997-02-25 | 2002-12-31 | Biotechnolog Forschung Mbh Gbf | Epothilons modificados nas cadeias laterais |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| SI0987268T1 (en) * | 1998-08-05 | 2002-10-31 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide |
| US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
| DE19907588A1 (de) * | 1999-02-22 | 2000-08-24 | Biotechnolog Forschung Gmbh | C-21 Modifizierte Epothilone |
| DE60006649T2 (de) | 1999-02-22 | 2004-09-30 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | C-21 modifizierte epothilone |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
| US7125893B1 (en) * | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| US6589968B2 (en) * | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| EE200300323A (et) | 2001-01-25 | 2003-10-15 | Bristol-Myers Squibb Company | Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine |
| WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| ES2304240T3 (es) | 2001-01-25 | 2008-10-01 | Bristol-Myers Squibb Company | Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer. |
| US6893859B2 (en) * | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| IL156988A0 (en) | 2001-02-20 | 2004-02-08 | Bristol Myers Squibb Co | Pharmaceutical compositions containing epothilone derivatives |
| KR20040028720A (ko) | 2001-02-20 | 2004-04-03 | 브리스톨-마이어스스퀴브컴파니 | 치료불응성 종양 치료용 에포틸론 유도체 |
| HUP0303895A3 (en) * | 2001-02-27 | 2007-06-28 | Biotechnolog Forschung Gmbh | Degradation of epothilones |
| HRP20030831B1 (en) | 2001-03-14 | 2012-08-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| WO2002098868A1 (en) | 2001-06-01 | 2002-12-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| IL163774A0 (en) * | 2002-03-08 | 2005-12-18 | Univ Newcastle | Combinations comprising epothilone derivatives andalkylating agents |
| ATE452896T1 (de) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| KR101173510B1 (ko) | 2002-08-23 | 2012-08-21 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도 |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| GB0221312D0 (en) * | 2002-09-13 | 2002-10-23 | Novartis Ag | Organic compounds |
| RS20050235A (en) | 2002-09-23 | 2007-06-04 | Bristol Myers Squibb Company, | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
| AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| TW200631609A (en) * | 2004-11-18 | 2006-09-16 | Bristol Myers Squibb Co | Enteric coated bead comprising ixabepilone, and preparation and administration thereof |
| EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
| RU2009125599A (ru) | 2006-12-04 | 2011-01-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы лечения рака cpg-богатой днк и купредоксинами |
| ES2625637T3 (es) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | Compuestos de unión al dominio BIR IAP |
| EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
| CN103442737B (zh) | 2011-01-20 | 2017-03-29 | 得克萨斯系统大学董事会 | Mri标记、递送和提取系统及其制造方法和用途 |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| WO2014075391A1 (zh) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物 |
| WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| JP2016520665A (ja) | 2013-06-11 | 2016-07-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ |
| IL245009B (en) | 2013-10-11 | 2022-08-01 | Asana Biosciences Llc | Protein-polymer-drug conjugates |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| AU2018290330A1 (en) | 2017-06-22 | 2020-01-02 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| EP3787691A1 (en) | 2018-05-04 | 2021-03-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| AU2019262521B2 (en) | 2018-05-04 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| WO2020092385A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| JP2022537543A (ja) | 2019-06-17 | 2022-08-26 | タグワークス ファーマシューティカルス ビー．ブイ． | 高速で且つ効率的なクリック放出の為の化合物 |
| CN118339280A (zh) | 2021-09-06 | 2024-07-12 | 维拉克萨生物技术有限责任公司 | 用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体 |
| JP2024543916A (ja) | 2021-11-25 | 2024-11-26 | ヴェラクサ バイオテック ゲーエムベーハー | 遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ） |
| EP4186529B1 (en) | 2021-11-25 | 2025-07-09 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| EP4444356A1 (en) | 2021-12-08 | 2024-10-16 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| US20250114489A1 (en) | 2022-02-15 | 2025-04-10 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| EP4602023A1 (en) | 2022-10-12 | 2025-08-20 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
| WO2024153789A1 (en) | 2023-01-20 | 2024-07-25 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| AU2024237490A1 (en) | 2023-03-10 | 2025-09-25 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctene with improved t-linker |
| WO2025021929A1 (en) | 2023-07-27 | 2025-01-30 | Veraxa Biotech Gmbh | Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same |
| WO2025056807A1 (en) | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025174248A1 (en) | 2024-02-16 | 2025-08-21 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctenes with "or gate" release |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993010121A1 (de) * | 1991-11-19 | 1993-05-27 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59610712D1 (de) * | 1995-11-17 | 2003-10-16 | Biotechnolog Forschung Gmbh | Epothilonderivate, herstellung und verwendung |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| PT975638E (pt) * | 1997-02-25 | 2002-12-31 | Biotechnolog Forschung Mbh Gbf | Epothilons modificados nas cadeias laterais |
-
1998
- 1998-02-25 PT PT98912388T patent/PT975638E/pt unknown
- 1998-02-25 HU HU0002189A patent/HU228851B1/hu unknown
- 1998-02-25 KR KR10-1999-7007773A patent/KR100494179B1/ko not_active Expired - Fee Related
- 1998-02-25 CZ CZ0286599A patent/CZ298027B6/cs not_active IP Right Cessation
- 1998-02-25 ES ES98912388T patent/ES2183338T3/es not_active Expired - Lifetime
- 1998-02-25 CA CA002281105A patent/CA2281105A1/en not_active Abandoned
- 1998-02-25 CN CN98802842A patent/CN1128803C/zh not_active Expired - Fee Related
- 1998-02-25 DE DE19880193T patent/DE19880193D2/de not_active Expired - Lifetime
- 1998-02-25 DE DE59805110T patent/DE59805110D1/de not_active Expired - Lifetime
- 1998-02-25 EP EP98912388A patent/EP0975638B1/de not_active Expired - Lifetime
- 1998-02-25 EP EP02001063A patent/EP1201666A3/de not_active Ceased
- 1998-02-25 AT AT98912388T patent/ATE221888T1/de active
- 1998-02-25 AU AU67249/98A patent/AU736062B2/en not_active Ceased
- 1998-02-25 ZA ZA981575A patent/ZA981575B/xx unknown
- 1998-02-25 IL IL13134398A patent/IL131343A/en not_active IP Right Cessation
- 1998-02-25 PL PL98335329A patent/PL190422B1/pl unknown
- 1998-02-25 JP JP53730098A patent/JP2001513098A/ja not_active Withdrawn
- 1998-02-25 WO PCT/EP1998/001060 patent/WO1998038192A1/de active IP Right Grant
- 1998-02-25 RU RU99120378/04A patent/RU2201932C2/ru not_active IP Right Cessation
- 1998-02-25 NZ NZ337195A patent/NZ337195A/en unknown
- 1998-02-25 CN CNA031597866A patent/CN1544436A/zh active Pending
- 1998-02-25 DK DK98912388T patent/DK0975638T3/da active
- 1998-02-25 BR BRPI9807742-2A patent/BR9807742B1/pt not_active IP Right Cessation
- 1998-02-26 AR ARP980100851A patent/AR011878A1/es unknown
- 1998-05-28 TW TW087102758A patent/TW480263B/zh not_active IP Right Cessation
-
1999
- 1999-08-17 US US09/376,754 patent/US6359140B1/en not_active Expired - Lifetime
- 1999-08-24 NO NO19994071A patent/NO327211B1/no not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993010121A1 (de) * | 1991-11-19 | 1993-05-27 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ298027B6 (cs) | Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu | |
| Moore et al. | Fontonamide and anhydrohapaloxindole A, two new alkaloids from the blue-green alga Hapalosiphon fontinalis | |
| EP4308168A1 (en) | Methods for preparing cyclooctenes and conjugates thereof | |
| RU2182154C2 (ru) | Фармацевтическая композиция, производные тритерпена | |
| AU705245B2 (en) | Sesquiterpene derivatives having antiviral activity | |
| CN1082509C (zh) | 从马比木分离的喜树碱骨架化合物及其作为新药物及治疗剂的合成子的用途 | |
| KR910008799B1 (ko) | 에피포도필로톡신 배당체의 4'-아실 유도체 | |
| Kohout et al. | Brassino steroids with androstane and pregnane skeleton | |
| Tapolcsányi et al. | The Mitsunobu inversion reaction of sterically hindered 17-hydroxy steroids | |
| US5876984A (en) | Sequiterpene derivatives having antiviral activity | |
| CS200538B2 (en) | Method of producing derivatives of oleandomycin | |
| JPH0121146B2 (cs) | ||
| KR100500498B1 (ko) | 에스트로겐혼합물의황산화방법 | |
| PL182354B1 (pl) | Sposób izomeryzacji ekwiliny PL PL PL PL | |
| Ishii et al. | Studies on lysergic acid diethylamide and related compounds. Part 8. Structural identification of new metabolites of lysergic acid diethylamide obtained by microbial transformation using Streptomyces roseochromogenes | |
| EP0987268B1 (en) | Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide | |
| Chéry et al. | Vinyl bis-sulfone methodology in thiosugars: selective access to chiral thiovinyl sulfones and PSE oxathianes | |
| Uoto et al. | Preparation of large macrocyclic tetra‐amines consisting of a methylene backbone and a cyclophane type skeleton | |
| WO2025171103A1 (en) | Amino acid derivatives and method of making the same | |
| HK1019600B (en) | Camtothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents | |
| Paulik et al. | Semisynthetic analogues of Buxus alkaloids | |
| MXPA99007546A (en) | Epothilones with a modified side chain | |
| CZ374292A3 (en) | Novel process for preparing brassinosteroids | |
| Golubovskaya et al. | Synthesis of 17α-Acetoxyestra-1, 3, 5 (10)-triene-3, 11α-diol. | |
| JPH08231501A (ja) | ラクタシスチン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20180225 |